Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | RAD52 | P43351 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20598175 | 0.96 | CYP19A1 (0.39) | CYP19A1ALDH1A1CYP1A2CA2ALOX5 | |
| SCHEMBL20598318 | 0.78 | CYP19A1 (0.44) | CYP19A1ALDH1A1CYP1A2ALOX5TDP1 | |
| SCHEMBL2602795 | 0.74 | CYP1A2 (0.47) | ALDH1A1CYP1A2CA2ALOX5 | |
| SCHEMBL18986552 | 0.74 | CYP1A2 (0.41) | CYP19A1ALDH1A1CYP1A2ALOX5 | |
| SCHEMBL11078686 | 0.73 | CYP19A1 (0.40) | CYP19A1ALDH1A1CYP1A2TDP1 | |
| SCHEMBL28813151 | 0.70 | CYP1A2 (0.43) | ALDH1A1CYP1A2ALOX5TDP1 | |
| SCHEMBL13130582 | 0.70 | CYP19A1 (0.43) | CYP19A1ALDH1A1CYP1A2 | |
| SCHEMBL18986553 | 0.70 | CYP1A2 (0.46) | CYP19A1ALDH1A1CYP1A2ALOX5 | |
| SCHEMBL27900437 | 0.70 | CYP1A2 (0.46) | CYP19A1ALDH1A1CYP1A2ALOX5 | |
| SCHEMBL4763973 | 0.69 | CYP1A2 (0.42) | ALDH1A1CYP1A2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108366938-B | Biaromatic vitamin D analogs | 帝斯曼知识产权资产管理有限公司 | 2021-08-24 | — | — | CN | disclosed |
| EP-3389606-B1 | BIAROMATIC VITAMIN D ANALOGS | DSM IP ASSETS BV (NL) | 2020-07-15 | — | — | EP | disclosed |
| US-10336675-B2 | Biaromatic vitamin D analogs | DSM IP ASSETS B.V. (NL) | 2019-07-02 | — | — | US | disclosed |
| US-20190002378-A1 | BIAROMATIC VITAMIN D ANALOGS | DSM IP ASSETS B.V. (NL) | 2019-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002378-A1 | BIAROMATIC VITAMIN D ANALOGS | CYP24A1, VDR, CYP2R1 | CYP19A1 13/4885ALDH1A1 386/4885CYP1A2 122/4885 |
| US-10336675-B2 | Biaromatic vitamin D analogs | CYP24A1, VDR, CYP2R1 | CYP19A1 13/4885ALDH1A1 386/4885CYP1A2 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.